All News

The implementation of targeted educational interventions might improve knowledge gaps, which pose great risk to patients, in type 2 diabetes (T2D) management.

N-3 polyunsaturated fatty acids (PUFAs) are essential nutrients, especially during pregnancy as they support neurodevelopment in offspring and improve pregnancy outcomes.

A panel discussion at the Outcomes 2024 SYNC National Conference touched upon many important themes in community pharmacy, including the evolving role of pharmacists, emerging tech, and key challenges going forward.

Complementary health approaches, like yoga or acupuncture, can be particularly appealing to patients seeking natural and non-invasive approaches to improve their health.

Check out a recap of important pharmacy news you might’ve missed this week, dispensed in small doses.

Test your pharmacy news knowledge with our weekly quiz.

A clinical trial showed that nivolumab plus chemotherapy significantly improved overall survival and progression-free survival compared with a chemotherapy combination alone.

Mind Medicine’s lysergide d-tartrate (MM120) demonstrated statistically significant and clinically meaningful improvements in anxiety symptoms in a phase 2b study.

As pharmacy benefit managers gain leverage to continue driving up drug prices, local pharmacies struggle to keep up and Congress has been called to act—but it might be too late.

The statement says the agency is talking with CMS to initiate new flexibilities, but multiple advocacy groups have said it’s not nearly enough.

Positive results from the FLOW trial demonstrate the potential for Ozempic to become the first GLP-1 treatment option for people living with type 2 diabetes and chronic kidney disease.

Following investigation by the independent testing laboratory, Valisure found acne products that contain up to 12 times the allowed of benzene.

Dexcom's Stelo will be available in summer 2024.

The agency approved denosumab-bddz under two brand names: Wyost and Jubbonti.

Health care professionals, industry leaders, and politicians gathered for a virtual roundtable to discuss the state of the PBM industry.

Clobetasol propionate ophthalmic suspension 0.05% is the first ophthalmic clobetasol propionate product approved by the FDA and is the first new ophthalmic steroid on the market in over 15 years.

In 2017, dupilumab became the first treatment approved in Canada for moderate to severe AD, as multiple clinical trials demonstrated its effectiveness and safety.

Check out a recap of important pharmacy news you might’ve missed this week, dispensed in small doses.

Test your pharmacy news knowledge with our weekly quiz: February 26 to March 1

Viking Therapeutics’ VK2735 met both of its primary and secondary endpoints in the VENTURE trial, demonstrating statistically significant reductions in body weight compared to placebo.

Physician assistants have pulled well ahead of pharmacists in a recent listing of top jobs in the health care profession.

Three times each year, the National Community Pharmacists Association holds intensive workshops that drill down into the nitty gritty of pharmacy ownership.

Pharmacy schools specialize in training students as experts in patient care—not as expert business owners.

These OTC products are recommended to address a variety of symptoms that occur during cold and flu seasons.

How much longer can independent pharmacists survive with the current method of reimbursement?

Your look at today’s health care headlines, including production challenges at a Aurobindo, Pfizer’s Super Bowl commercial, and Novo Nordisk’s semaglutide lawsuits.

The Affordable Care Act mandates that contraceptives must be covered by health plans and insurers without cost-sharing.

The lawsuit claims several pharmacy benefit managers, including Express Scripts and OptumRx, collaborated with manufacturers in “deceptive” and “dangerous” marketing.